Sanara MedTech Inc.
NASDAQ:SMTIMedical - Instruments & Supplies
+$0.73 today
- Market cap
- $300.55M
- Beta
- 1.19
- P/E (TTM)
- -5.7
- EPS (TTM)
- -$3.86
Volume 0.07M
Average 0.06M
SMTI Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Sanara MedTech Inc.NASDAQ: SMTI
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation declines year over year
Q1 FY2026 stock-based compensation of $1.03M fell 21.2% year over year, ahead of the -91.0% change in trailing-twelve-month stock-based compensation. Over 3 fiscal years it compounded at -35.7% a year.
Context
- Stock-based compensation amounted to 0.7% of revenue in FY2025, down 4.4 pp from a year earlier.
- Stock-based compensation increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -21.2% holds above the trailing-twelve-month pace of -91.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 718.71K USD
- Year-over-year change
- -83.8%
- 4-year CAGR
- -28.0%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 718.71K | -83.8% |
| FY2024 | 2024-12-31 | 4.44M | +28.9% |
| FY2023 | 2023-12-31 | 3.44M | +27.4% |
| FY2022 | 2022-12-31 | 2.7M | +1.3% |
| FY2021 | 2021-12-31 | 2.67M | — |
Stock-Based Compensation vs competitors
How SMTI compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -91.0% is the lowest of 10, against a peer median of -7.7%.
- Stock-based compensation amounts to 0.4% of revenue for SMTI, versus a peer median of 3.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $28.16M USD | -29.2% | +18.8% | 3.7% | |
| LTM Mar 2026 | $19.27M USD | -0.0% | +25.6% | 335.8% | |
| LTM Mar 2026 | $17.06M USD | +187.5% | +18.7% | 4.9% | |
| LTM Mar 2026 | $11.67M USD | -30.6% | +0.2% | 14.7% | |
| LTM Mar 2026 | $9.43M USD | -7.7% | -2.3% | 30.2% | |
| LTM Mar 2026 | $9.27M USD | +29.4% | +20.6% | 3.2% | |
| LTM Mar 2026 | $7.95M USD | -35.1% | -8.6% | 3.6% | |
| LTM Mar 2026 | $2.4M USD | +47.3% | -22.9% | 3.5% | |
| LTM Apr 2026 | CA$1.86M CAD | -54.1% | -21.4% | 0.3% | |
| LTM Mar 2026 | $442.14K USD | -91.0% | -35.7% | 0.4% | |
| Peer median (excluding SMTI) | — | -7.7% | +0.2% | 3.7% | |
Competitors are the stored peer set for SMTI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (7.99M) | (8.09M) | (4.44M) | (9.91M) | (27.66M) |
| Depreciation & Amortization | 596.98K | 2.37M | 3.68M | 4.92M | 28.56M |
| Deferred Income Tax | 0 | (5.84M) | 0 | 0 | 0 |
| Stock-Based Compensation | 2.67M | 2.7M | 3.44M | 4.44M | 718.71K |
| Change in Working Capital | (1.18M) | 517.62K | (3.28M) | (911.72K) | (3.84M) |
| Accounts Receivables | (774.81K) | (2.27M) | (1.73M) | (4.54M) | 4.03M |
| Inventory | (1.15M) | (517.27K) | (1.55M) | 1.44M | (431.33K) |
| Accounts Payables | 99.13K | (423.75K) | 575.15K | (471.21K) | 1.24M |
| Other Working Capital | 645.56K | 3.73M | (577.32K) | 2.66M | (8.68M) |
| Other Non-Cash Items | 1.1M | 2.79M | (2.64M) | 1.44M | 9.02M |
| Operating Cash Flow | (4.81M) | (5.55M) | (3.25M) | (23.78K) | 6.79M |
| Capital Expenditures | (750.45K) | (747.02K) | (265.25K) | (229.3K) | (4.63M) |
| Acquisitions (Net) | 0 | (2.52M) | (9.94M) | 0 | 0 |
| Purchases of Investments | (4.53M) | (250K) | 0 | (5.3M) | 9.48M |
| Sales of Investments | 0 | 0 | 0 | 0 | (2.96M) |
| Other Investing Activities | (578.59K) | (598.45K) | 650 | (1.1M) | (10.47M) |
| Investing Cash Flow | (5.28M) | (3.51M) | (10.21M) | (6.61M) | (8.36M) |
| Debt Repayment | 0 | 0 | 9.69M | 19.59M | 0 |
| Common Stock Issued | 28.94M | 0 | 911.37K | 0 | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (642.53K) | (627.35K) | (958.59K) | (2.15M) | (8.48M) |
| Financing Cash Flow | 28.3M | (627.35K) | 9.64M | 17.37M | (8.48M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 18.2M | (9.69M) | (3.81M) | 10.73M | (10.03M) |
| Free Cash Flow | (5.56M) | (6.3M) | (3.51M) | (253.08K) | 2.16M |
Sanara MedTech Inc.
NASDAQ:SMTI
Intrinsic Alpha fair value
Locked
Current Price
$32.73
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.